Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation
Elizabeth Hexner
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorRon Hoffman
Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY, USA
Search for more papers by this authorJohn Mascarenhas
Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY, USA
Search for more papers by this authorMartin Carroll
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorRegina Clementi
Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA
Search for more papers by this authorDebra Bensen-Kennedy
Cephalon, Inc., now a wholly owned subsidiary of Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA
Search for more papers by this authorCorresponding Author
Alison Moliterno
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Correspondence: Alison Moliterno, Johns Hopkins University School of Medicine, Traylor Building, Room 912, 720 Rutland Ave, Baltimore, MD 21205, USA.
E-mail: [email protected]
Search for more papers by this authorElizabeth Hexner
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorRon Hoffman
Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY, USA
Search for more papers by this authorJohn Mascarenhas
Mount Sinai School of Medicine, Tisch Cancer Institute, New York, NY, USA
Search for more papers by this authorMartin Carroll
University of Pennsylvania, Philadelphia, PA, USA
Search for more papers by this authorRegina Clementi
Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA
Search for more papers by this authorDebra Bensen-Kennedy
Cephalon, Inc., now a wholly owned subsidiary of Teva Branded Pharmaceutical Products R&D, Inc., Frazer, PA, USA
Search for more papers by this authorCorresponding Author
Alison Moliterno
Johns Hopkins University School of Medicine, Baltimore, MD, USA
Correspondence: Alison Moliterno, Johns Hopkins University School of Medicine, Traylor Building, Room 912, 720 Rutland Ave, Baltimore, MD 21205, USA.
E-mail: [email protected]
Search for more papers by this authorSummary
JAK2-V617F is central to the pathogenesis of myeloproliferative neoplasms. We examined whether lestaurtinib decreased JAK2-V617F allele burden and evaluated its clinical benefits and tolerability in patients with polycythaemia vera (PV) and essential thrombocythaemia (ET). This phase 2, open-label, multicentre study was designed to detect ≥15% reduction in JAK2-V617F allele burden in 15% of patients. Eligible patients received lestaurtinib 80 mg twice daily for 18 weeks and could participate in a 1-year extension phase of treatment. Of 39 enrolled patients, 27 (69%) had PV; 12 (31%) had ET. While the pre-specified responder rate of 15% was not met, lestaurtinib modestly reduced JAK2-V617F allele burden and reduced spleen size in a subset of patients. Of 37 patients in the full efficacy analysis, 5 (14%) responded clinically. Every patient had ≥1 adverse event, most commonly gastrointestinal (95%). Fifteen patients (38%) experienced serious adverse events; 23 (59%) withdrew due to adverse events. This is the first reported study of JAK2-inhibitor treatment in patients with PV/ET and highlights both the need for further studies to assess the role of JAK2 inhibition in treatment of PV/ET and the use of JAK2-V617F as a biomarker for response. This trial was registered at www.clinicaltrials.gov as NCT00586651.
References
- Antonioli, E., Carobbio, A., Pieri, L., Pancrazzi, A., Guglielmelli, P., Delaini, F., Ponziani, V., Bartalucci, N., Tozzi, L., Bosi, A., Rambaldi, A., Barbui, T. & Vannucchi, A.M. (2010) Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 95, 1435–1438.
- Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054–1061.
- Berk, P.D., Goldberg, J.D., Silverstein, M.N., Weinfeld, A., Donovan, P.B., Ellis, J.T., Landaw, S.A., Laszlo, J., Najean, Y., Pisciotta, A.V. & Wasserman, L.R. (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New England Journal of Medicine, 304, 441–447.
- Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine, 332, 1132–1136.
- Guglielmelli, P., Biamonte, F., Score, J., Hidalgo-Curtis, C., Cervantes, F., Maffioli, M., Fanelli, T., Ernst, T., Winkelman, N., Jones, A.V., Zoi, K., Reiter, A., Duncombe, A., Villani, L., Bosi, A., Barosi, G., Cross, N.C. & Vannucchi, A.M. (2011) EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 118, 5227–5234.
- Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33–45.
- Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366, 787–798.
- Hexner, E.O., Serdikoff, C., Jan, M., Swider, C.R., Robinson, C., Yang, S., Angeles, T., Emerson, S.G., Carroll, M., Ruggeri, B. & Dobrzanski, P. (2008) Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood, 111, 5663–5671.
- James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144–1148.
- Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A. & Cross, N.C. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, 106, 2162–2168.
- Kiladjian, J.J., Cassinat, B., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Menot, M.L., Massonnet, G., Dutel, J.L., Ghomari, K., Rousselot, P., Grange, M.J., Chait, Y., Vainchenker, W., Parquet, N., Abdelkader-Aljassem, L., Bernard, J.F., Rain, J.D., Chevret, S., Chomienne, C. & Fenaux, P. (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood, 108, 2037–2040.
- Kiladjian, J.J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C. & Fenaux, P. (2008) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065–3072.
- Klco, J.M., Vij, R., Kreisel, F.H., Hassan, A. & Frater, J.L. (2010) Molecular pathology of myeloproliferative neoplasms. American Journal of Clinical Pathology, 133, 602–615.
- Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779–1790.
- Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350, 114–124.
- Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387–397.
- Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., Baccarani, M., Cripe, L.D., Tallman, M.S., Meloni, G., Godley, L.A., Langston, A.A., Amadori, S., Lewis, I.D., Nagler, A., Stone, R., Yee, K., Advani, A., Douer, D., Wiktor-Jedrzejczak, W., Juliusson, G., Litzow, M.R., Petersdorf, S., Sanz, M., Kantarjian, H.M., Sato, T., Tremmel, L., Bensen-Kennedy, D.M., Small, D. & Smith, B.D. (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 117, 3294–3301.
- Li, J., Spensberger, D., Ahn, J.S., Anand, S., Beer, P.A., Ghevaert, C., Chen, E., Forrai, A., Scott, L.M., Ferreira, R., Campbell, P.J., Watson, S.P., Liu, P., Erber, W.N., Huntly, B.J., Ottersbach, K. & Green, A.R. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood, 116, 1528–1538.
- Moliterno, A.R., Williams, D.M., Rogers, O. & Spivak, J.L. (2006) Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood, 108, 3913–3915.
- Moliterno, A.R., Williams, D.M., Rogers, O., Isaacs, M.A. & Spivak, J.L. (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Experimental Hematology, 36, 1480–1486.
- Pardanani, A., Gotlib, J.R., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R.M., Silverman, M.H., Gilliland, D.G., Shorr, J. & Tefferi, A. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology, 29, 789–796.
- Santos, F.P., Kantarjian, H.M., Jain, N., Manshouri, T., Thomas, D.A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J. & Verstovsek, S. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 115, 1131–1136.
- Scott, L.M., Scott, M.A., Campbell, P.J. & Green, A.R. (2006) Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood, 108, 2435–2437.
- Stein, B.L. & Moliterno, A.R. (2010) Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. JAMA: the Journal of the American Medical Association, 303, 2513–2518.
- Stein, B.L., Williams, D.M., Wang, N.Y., Rogers, O., Isaacs, M.A., Pemmaraju, N., Spivak, J.L. & Moliterno, A.R. (2010) Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica, 95, 1090–1097.
- Stein, B.L., Williams, D.M., O'Keefe, C., Rogers, O., Ingersoll, R.G., Spivak, J.L., Verma, A., Maciejewski, J.P., McDevitt, M.A. & Moliterno, A.R. (2011) Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica, 96, 1462–1469.
- Ugo, V., Marzac, C., Teyssandier, I., Larbret, F., Lecluse, Y., Debili, N., Vainchenker, W. & Casadevall, N. (2004) Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Experimental Hematology, 32, 179–187.
- Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Pardanani, A. & Tefferi, A. (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 22, 1299–1307.
- Verstovsek, S. (2009) Therapeutic potential of JAK2 inhibitors. Hematology: American Society of Hematology Education Program, 2009, 636–642.
10.1182/asheducation-2009.1.636 Google Scholar
- Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr, Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799–807.
- Zalcberg, I.R., Ayres-Silva, J., de Azevedo, A.M., Solza, C., Daumas, A. & Bonamino, M. (2011) Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica, 96, e18–e20.
Citing Literature
